Lipid Metabolism Practice Questions

Q: Arachidonic acid is synthesized from which of the following?

Linoleic acid. **Explanation:** Arachidonic acid is a **20-carbon polyunsaturated fatty acid (PUFA)** with four double bonds (C20:4, ω-6). In the human body, it is synthesized from **Linoleic acid** (C18:2, ω-6). **1. Why Linoleic acid is correct:** Linoleic acid is an **essential fatty acid** because humans lack the enzymes (desaturases) to introduce double bonds beyond carbon 9. However, once linoleic acid is consumed, the body can convert it into arachidonic acid through a three-step pathway: * **Desaturation:** Addition of a double bond by $\Delta^6$-desaturase. * **Elongation:** Addition of two carbons. * **Desaturation:** Addition of another double bond by $\Delta^5$-desaturase. Since both belong to the **omega-6 (ω-6) family**, linoleic acid serves as the direct precursor. **2. Why other options are incorrect:** * **Stearic acid (C18:0):** A saturated fatty acid. While it can be desaturated to oleic acid, it cannot be converted into essential ω-3 or ω-6 PUFAs. * **Linolenic acid (C18:3, ω-3):** This is the precursor for **EPA** (Eicosapentaenoic acid) and **DHA** (Docosahexaenoic acid). It belongs to the ω-3 family and cannot be converted into ω-6 arachidonic acid. * **Oleic acid (C18:1, ω-9):** A monounsaturated fatty acid synthesized by the body. It cannot be converted into polyunsaturated essential fatty acids. **Clinical Pearls for NEET-PG:** * **Prostaglandin Synthesis:** Arachidonic acid is the primary substrate for the synthesis of eicosanoids (prostaglandins, thromboxanes, and leukotrienes) via the COX and LOX pathways. * **Essentiality:** Arachidonic acid becomes "conditionally essential" only if linoleic acid is deficient in the diet. * **Rate-limiting step:** The $\Delta^6$-desaturase reaction is the rate-limiting step in the conversion of linoleic to arachidonic acid.

Q: What is the inhibitor of Carnitine Palmitoyl Transferase-1?

ATP. **Explanation:** The correct answer is **ATP**. **1. Why ATP is correct:** Carnitine Palmitoyl Transferase-1 (CPT-1) is the rate-limiting enzyme of **Beta-oxidation**, responsible for transporting long-chain fatty acids into the mitochondria. Beta-oxidation is a catabolic process aimed at generating energy. According to the principles of metabolic regulation, high energy levels in the cell (signaled by a high **ATP/ADP ratio**) inhibit catabolic pathways. Therefore, ATP acts as an allosteric inhibitor of CPT-1 to prevent the unnecessary breakdown of fatty acids when energy supplies are already sufficient. **2. Why the other options are incorrect:** * **Acetoacetate:** This is a ketone body. While high levels of ketone bodies indicate active lipid metabolism, they do not directly inhibit CPT-1. * **Succinyl CoA:** This is an intermediate of the TCA cycle and heme synthesis. It does not play a direct regulatory role in the carnitine shuttle. * **Acyl CoA:** This is the substrate for the CPT-1 reaction. High levels of substrate typically drive a reaction forward rather than inhibiting it. **3. High-Yield Clinical Pearls for NEET-PG:** * **The Most Potent Inhibitor:** While ATP inhibits CPT-1, the most physiologically significant inhibitor frequently tested is **Malonyl-CoA**. It prevents the simultaneous occurrence of fatty acid synthesis and oxidation (preventing a "futile cycle"). * **Location:** CPT-1 is located on the **outer mitochondrial membrane**, whereas CPT-2 is on the inner membrane. * **Clinical Correlation:** CPT-1 deficiency typically presents as non-ketotic hypoglycemia and hepatomegaly, often triggered by fasting.

Q: Which of the following are primary bile acids synthesized in the liver?

All of the above. **Explanation:** Bile acid synthesis is the primary pathway for cholesterol excretion in the body. This process occurs in the liver and involves several enzymatic steps, most notably the rate-limiting step catalyzed by **7-alpha-hydroxylase**. 1. **Primary Bile Acids:** These are synthesized directly from cholesterol in the hepatocytes. The two main primary bile acids are **Cholic acid** and **Chenodeoxycholic acid**. 2. **Conjugation:** Before leaving the liver, these primary bile acids are conjugated with amino acids—either **Glycine** or **Taurine**. This process increases their solubility and ionization at physiological pH. Therefore, **Glycocholic acid** (Cholic acid + Glycine) is a conjugated form of a primary bile acid and is also synthesized within the liver. **Analysis of Options:** * **A & B (Cholic & Chenodeoxycholic acid):** These are the fundamental primary bile acids produced from cholesterol. * **C (Glycocholic acid):** Since conjugation occurs in the liver prior to secretion into the bile canaliculi, conjugated forms like glycocholic acid are also considered primary bile products of the liver. * **D (All of the above):** This is correct as all three substances are synthesized/formed within the hepatic parenchyma. **High-Yield Clinical Pearls for NEET-PG:** * **Secondary Bile Acids:** These are formed in the **intestine** by the action of bacterial enzymes (dehydroxylation) on primary bile acids. They include **Deoxycholic acid** (from cholic) and **Lithocholic acid** (from chenodeoxycholic). * **Rate-limiting enzyme:** 7-alpha-hydroxylase (inhibited by bile acids, stimulated by cholesterol). * **Enterohepatic Circulation:** Approximately 95% of bile acids are reabsorbed in the **terminal ileum** and returned to the liver. * **Steatorrhea:** Malabsorption of fats occurs if bile acid synthesis or ileal reabsorption is impaired.

Q: Apo-E deficiency is seen in which type of hypolipoproteinemia?

Type III hypolipoproteinemia. **Explanation:** The correct answer is **Type III Hyperlipoproteinemia**, also known as **Dysbetalipoproteinemia** or Broad Beta Disease. **Why Type III is Correct:** Type III hyperlipoproteinemia is caused by a deficiency or polymorphism of **Apolipoprotein E (Apo-E)**. Specifically, patients typically have the **ApoE-2/E-2 phenotype**. Apo-E is essential for the hepatic recognition and uptake of **Chylomicron remnants** and **IDL (VLDL remnants)** via the LDL receptor-related protein (LRP). When Apo-E is defective, these remnants accumulate in the plasma, leading to elevated cholesterol and triglycerides. A characteristic clinical finding is **Palmar Xanthomas** (Xanthoma striatum palmare). **Why Other Options are Incorrect:** * **Type I (Familial Chylomicronemia):** Caused by a deficiency of **Lipoprotein Lipase (LPL)** or **Apo C-II**. It is characterized by severe elevations in Chylomicrons and eruptive xanthomas. * **Type II (Familial Hypercholesterolemia):** Type IIa is due to a deficiency in **LDL receptors**, while Type IIb involves increased VLDL as well. Apo-E is not the primary defect here. * **Type IV (Familial Hypertriglyceridemia):** Characterized by isolated elevation of **VLDL** due to hepatic overproduction, not an Apo-E deficiency. **High-Yield NEET-PG Pearls:** * **Apo-E Function:** Mediates remnant uptake (Remnant = "E"ntry to liver). * **Electrophoresis:** Type III shows a characteristic **"Broad Beta Band"** (merging of VLDL and LDL bands). * **Apo-E4 Link:** While Apo-E2 is linked to Type III hyperlipoproteinemia, the **Apo-E4** isoform is a significant risk factor for **Alzheimer’s disease**. * **Treatment:** Fibrates are the first-line treatment for Type III to reduce triglyceride-rich remnants.

Q: Which of the following oils contains a high quantity of saturated fatty acids?

Coconut oil. **Explanation:** The core concept tested here is the classification of dietary fats based on their degree of saturation. Fatty acids are categorized into **Saturated Fatty Acids (SFA)**, which have no double bonds, and **Unsaturated Fatty Acids (UFA)**, which contain one or more double bonds. **Why Coconut Oil is Correct:** While most plant-derived oils are rich in unsaturated fats, **Coconut oil** is a notable exception. It contains approximately **90-92% saturated fatty acids**, primarily in the form of Medium-Chain Triglycerides (MCTs) like Lauric acid (C12), Myristic acid (C14), and Palmitic acid (C16). Because it lacks double bonds, it remains solid at room temperature and is highly resistant to oxidation. **Why the Other Options are Incorrect:** * **Sunflower oil, Safflower oil, and Soybean oil** are all categorized as **Polyunsaturated Fatty Acids (PUFAs)**. * **Safflower oil** is particularly high in Linoleic acid (Omega-6), making it one of the most unsaturated vegetable oils. * **Soybean oil** contains a mix of Linoleic acid and Alpha-linolenic acid (Omega-3). * **Sunflower oil** is a rich source of Vitamin E and Linoleic acid. **High-Yield NEET-PG Pearls:** 1. **MCT Advantage:** The MCTs in coconut oil are absorbed directly into the portal circulation without requiring chylomicron formation or pancreatic lipase, making them a preferred energy source in malabsorption syndromes. 2. **P/S Ratio:** The Polyunsaturated to Saturated fat ratio is an indicator of the "healthiness" of an oil. A higher ratio is generally considered cardioprotective. 3. **Essential Fatty Acids:** Remember that Linoleic (ω-6) and Alpha-linolenic (ω-3) acids are "essential" because the human body lacks the enzymes (desaturases) to introduce double bonds beyond carbon 9. 4. **Palm Oil:** Like coconut oil, palm oil is another plant source high in saturated fats (Palmitic acid).

Q: Which of the following compounds directly inhibits the expression of the HMG-CoA reductase gene?

Cholesterol. **Explanation:** The correct answer is **Cholesterol (Option D)**. **Mechanism of Action:** HMG-CoA reductase is the rate-limiting enzyme in cholesterol biosynthesis. Its regulation occurs at multiple levels, most notably through **transcriptional control**. When intracellular cholesterol levels are high, cholesterol (and its derivatives like oxysterols) inhibits the expression of the HMG-CoA reductase gene. This process involves **SREBP (Sterol Regulatory Element-Binding Protein)** and **SCAP (SREBP Cleavage-Activating Protein)**. When cholesterol is abundant, it binds to SCAP, keeping the SREBP-SCAP complex anchored in the endoplasmic reticulum. This prevents SREBP from moving to the nucleus to act as a transcription factor, thereby decreasing the synthesis of HMG-CoA reductase mRNA. **Analysis of Incorrect Options:** * **A. Superoxide Dismutase:** This is an antioxidant enzyme that neutralizes free radicals; it has no role in the cholesterol biosynthetic pathway. * **B. HMG-CoA:** This is the substrate for the enzyme, not a transcriptional inhibitor. * **C. Isopentenyl pyrophosphate:** This is an intermediate in the mevalonate pathway. While it is a precursor to cholesterol, it does not directly regulate gene expression of the reductase. **High-Yield Clinical Pearls for NEET-PG:** * **Statins:** These are competitive inhibitors of HMG-CoA reductase. * **Hormonal Regulation:** HMG-CoA reductase is **activated by Insulin** (via dephosphorylation) and **inhibited by Glucagon/Epinephrine** (via phosphorylation by AMPK). * **Degradation:** High cholesterol also promotes the rapid proteolysis (ubiquitination) of the HMG-CoA reductase enzyme itself. * **Location:** The enzyme is located in the **Endoplasmic Reticulum (ER)** membrane.

Q: A 15-year-old male presents with abdominal pain. General examination reveals xanthomas in clusters on his back, buttocks, arms, and legs. Percussion indicates hepatomegaly and splenomegaly. What is the most probable diagnosis for this child?

Type I Hyperlipoproteinemia. ### Explanation **Correct Option: A. Type I Hyperlipoproteinemia** The clinical triad of **eruptive xanthomas** (clusters on the back and buttocks), **hepatosplenomegaly**, and **abdominal pain** (due to acute pancreatitis) in a young patient is classic for Type I Hyperlipoproteinemia (Familial Chylomicronemia Syndrome). * **Mechanism:** It is caused by a deficiency in **Lipoprotein Lipase (LPL)** or its cofactor **Apo C-II**. * **Pathophysiology:** This leads to an inability to clear chylomicrons from the blood, resulting in massive hypertriglyceridemia. The milky appearance of plasma and "creamy layer" on standing are characteristic laboratory findings. **Incorrect Options:** * **B & C (Hypercholesterolemia):** These typically present with elevated LDL and cholesterol. Clinical signs include **tendon xanthomas** (Achilles) and xanthelasma, rather than eruptive xanthomas and hepatosplenomegaly. They are associated with premature atherosclerosis, not acute pancreatitis. * **D (Abetalipoproteinemia):** This is a deficiency of Microsomal Triglyceride Transfer Protein (MTP), leading to an absence of Apo B-48 and B-100. Patients present with malabsorption, fat-soluble vitamin deficiency, and **acanthocytosis** (spur cells), with very *low* lipid levels. **High-Yield Clinical Pearls for NEET-PG:** * **Type I:** High Chylomicrons; Deficiency of LPL/Apo C-II; Risk of Pancreatitis (No increased risk of atherosclerosis). * **Type IIa:** High LDL; Deficiency of LDL receptors; Risk of early MI and Tendon Xanthomas. * **Type III (Dysbetalipoproteinemia):** Deficiency of **Apo E**; characterized by **Palmar Xanthomas**. * **Type IV:** High VLDL; associated with obesity and insulin resistance.

Q: Which fatty acid is not synthesized in humans?

Linoleic acid. ### Explanation **1. Why Linoleic Acid is the Correct Answer:** Linoleic acid (18:2; Δ9,12) is an **essential fatty acid** because humans lack the enzymes (**Δ12 and Δ15 desaturases**) required to introduce double bonds beyond the Δ9 position of a fatty acid chain. These enzymes are only present in plants. Since humans cannot synthesize double bonds at the ω-6 or ω-3 positions, linoleic acid must be obtained through the diet. **2. Analysis of Incorrect Options:** * **Palmitic acid (16:0):** This is the primary product of the **Fatty Acid Synthase (FAS)** complex in the cytosol. It is the first fatty acid produced during de novo lipogenesis. * **Stearic acid (18:0):** This is synthesized by the elongation of palmitic acid in the mitochondria and endoplasmic reticulum. * **Oleic acid (18:1; Δ9):** Humans possess the **Δ9-desaturase** enzyme, which can introduce a single double bond at the 9th carbon of stearic acid to form oleic acid (an omega-9 fatty acid). **3. NEET-PG High-Yield Clinical Pearls:** * **Essential Fatty Acids (EFAs):** There are two primary EFAs: **Linoleic acid** (ω-6) and **Alpha-linolenic acid** (ω-3). * **Arachidonic acid:** Often called "semi-essential." It can be synthesized from linoleic acid. However, if linoleic acid is deficient in the diet, arachidonic acid becomes essential. * **Clinical Deficiency:** EFA deficiency leads to **Phrynoderma** (follicular hyperkeratosis/toad skin), poor wound healing, and alopecia. * **Key Enzyme:** The conversion of linoleic acid to arachidonic acid involves the enzyme **Δ6-desaturase**, which is the rate-limiting step in this pathway.

Q: Which of the following phospholipids does not contain glycerol?

Sphingomyelin. **Explanation:** Phospholipids are categorized into two main groups based on their alcohol backbone: **Glycerophospholipids** (glycerol backbone) and **Sphingophospholipids** (sphingosine backbone). **Why Sphingomyelin is the correct answer:** Sphingomyelin is the only clinically significant phospholipid that does **not** contain glycerol. Instead, it contains **sphingosine**, an 18-carbon amino alcohol. Its structure consists of a sphingosine backbone, a long-chain fatty acid (forming Ceramide), and a phosphorylcholine head group. It is a major structural component of the myelin sheath surrounding nerve fibers. **Why the other options are incorrect:** * **Lecithin (Phosphatidylcholine):** This is the most abundant glycerophospholipid in cell membranes. It consists of a glycerol backbone, two fatty acids, and a phosphate group attached to choline. * **Phosphatidyl serine:** This is a glycerophospholipid where the phosphate group is linked to the amino acid serine. It is crucial for apoptosis signaling when it flips to the outer leaflet of the cell membrane. * **Phosphatidyl inositol:** This is a glycerophospholipid containing the sugar alcohol inositol. It serves as a precursor for second messengers like $IP_3$ and $DAG$. **High-Yield NEET-PG Pearls:** * **Niemann-Pick Disease:** A lysosomal storage disorder caused by a deficiency in **Sphingomyelinase**, leading to the accumulation of sphingomyelin (characterized by "foam cells" and a cherry-red spot on the macula). * **L/S Ratio:** The Lecithin/Sphingomyelin ratio in amniotic fluid is used to assess fetal lung maturity. A ratio $>2$ indicates mature lungs. * **Dipalmitoylphosphatidylcholine (DPPC):** A specific type of Lecithin that is the major constituent of lung surfactant.

Q: Which of the following is an example of a monounsaturated fatty acid?

Oleic acid. **Explanation:** Fatty acids are classified based on the presence and number of double bonds in their hydrocarbon chain. **Monounsaturated Fatty Acids (MUFAs)** contain exactly one double bond. **1. Why Oleic acid is correct:** Oleic acid is a 18-carbon fatty acid with one double bond at the 9th carbon position (18:1; Δ9). It is the most common MUFA found in nature (e.g., olive oil) and is synthesized in the body by the enzyme **Stearoyl-CoA desaturase**. **2. Analysis of incorrect options:** * **Arachidonic acid:** This is a **Polyunsaturated Fatty Acid (PUFA)** with 20 carbons and four double bonds (20:4; Δ5, 8, 11, 14). It is a precursor for eicosanoids (prostaglandins, leukotrienes). * **Linolenic acid:** This is a PUFA. α-Linolenic acid (ALA) has 18 carbons and three double bonds (18:3; Δ9, 12, 15). It is an **essential fatty acid** (Omega-3 series). * **Lysine:** This is an **essential amino acid**, not a fatty acid. It is purely ketogenic and plays a role in protein synthesis and collagen cross-linking. **High-Yield Facts for NEET-PG:** * **Essential Fatty Acids:** Linoleic acid (18:2) and α-Linolenic acid (18:3). Humans lack the enzymes (Δ12 and Δ15 desaturases) to introduce double bonds beyond the Δ9 position. * **Palmitoleic acid (16:1):** Another important MUFA often tested. * **Prostaglandin Precursor:** Arachidonic acid is the primary substrate for the Cyclooxygenase (COX) pathway. * **Clinical Link:** Diets rich in MUFAs (like the Mediterranean diet) are associated with a reduced risk of cardiovascular disease as they lower LDL cholesterol without significantly decreasing HDL.

Question 1

Arachidonic acid is synthesized from which of the following?

Accepted Answer

Linoleic acid

Answer

Stearic acid

Answer

Linolenic acid

Answer

Oleic acid

Question 2

What is the inhibitor of Carnitine Palmitoyl Transferase-1?

Accepted Answer

ATP

Answer

Acetoacetate

Answer

Succinyl CoA

Answer

Acyl CoA

Question 3

Which of the following are primary bile acids synthesized in the liver?

Accepted Answer

All of the above

Answer

Cholic acid

Answer

Chenodeoxycholic acid

Answer

Glycocholic acid

Question 4

Apo-E deficiency is seen in which type of hypolipoproteinemia?

Accepted Answer

Type III hypolipoproteinemia

Answer

Type I hypolipoproteinemia

Answer

Type II hypolipoproteinemia

Answer

Type IV hypolipoproteinemia

Question 5

Which of the following oils contains a high quantity of saturated fatty acids?

Accepted Answer

Coconut oil

Answer

Sunflower oil

Answer

Safflower oil

Answer

Soybean oil

Question 6

Which of the following compounds directly inhibits the expression of the HMG-CoA reductase gene?

Accepted Answer

Cholesterol

Answer

Superoxide Dismutase

Answer

HMG-CoA

Answer

Isopentenyl pyrophosphate

Question 7

A 15-year-old male presents with abdominal pain. General examination reveals xanthomas in clusters on his back, buttocks, arms, and legs. Percussion indicates hepatomegaly and splenomegaly. What is the most probable diagnosis for this child?

Accepted Answer

Type I Hyperlipoproteinemia

Answer

Autosomal Dominant Hypercholesterolemia Type I

Answer

Autosomal Recessive Hypercholesterolemia

Answer

Abetalipoproteinemia

Question 8

Which fatty acid is not synthesized in humans?

Accepted Answer

Linoleic acid

Answer

Oleic acid

Answer

Palmitic acid

Answer

Stearic acid

Question 9

Which of the following phospholipids does not contain glycerol?

Accepted Answer

Sphingomyelin

Answer

Lecithin

Answer

Phosphatidyl serine

Answer

Phosphatidyl inositol

Question 10

Which of the following is an example of a monounsaturated fatty acid?

Accepted Answer

Oleic acid

Answer

Arachidonic acid

Answer

Linolenic acid

Answer

Lysine

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?